Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 2.
doi: 10.1002/ijc.35426. Online ahead of print.

Epigenetic reprogramming in multiple myeloma-Challenges and opportunities

Subhasree Kumar  1 , Lev M Kats  1   2 , Emily Gruber  1
Affiliations
Review

Epigenetic reprogramming in multiple myeloma-Challenges and opportunities

Subhasree Kumar et al. Int J Cancer. .

Abstract

In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly. Multiple myeloma is characterised by high levels of inter- and intra-patient heterogeneity at both the genetic and epigenetic levels. Understanding the many layers of genetic and non-genetic evolution and their interplay is crucial to improve patient outcomes. In this short review, we discuss the most common and extensively characterised epigenetic alterations that occur during myeloma development. We also touch on emerging approaches to reverse the aberrant epigenome of myeloma cells as a treatment strategy.

Keywords: epigenetic drugs; epigenetics; multiple myeloma.

PubMed Disclaimer

References

REFERENCES

    1. Zamagni E, Barbato S, Cavo M. How I treat high‐risk multiple myeloma. Blood. 2022;139(19):2889‐2903.
    1. Dima D, Jiang D, Singh DJ, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022;14(17):4082.
    1. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100‐113.
    1. Pawlyn C, Morgan GJ. Evolutionary biology of high‐risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543‐556.
    1. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467‐472.

LinkOut - more resources